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transcriptomics and Eimeria-mouse model to characterize host
determinants of parasite development.
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Background: Leptospirosis is aworldwide zoonotic disease and
serious underreported public health problem. In Katavi humans,
livestock and wildlife live in close proximity which exposes them
to a number of zoonotic infections
Methods & Materials: A cross sectional epidemiological sur-
vey was carried out in Katavi region, Tanzania to determine the
seroprevalence of Leptospira spp infection in humans, domestic
and wild animals. A total of 1351 domestic ruminants were ran-
domly selected from 138 Agro-pastoral households. Opportunistic
sampling of wild animals was also carried out. Blood samples was
collected from jugular veins of apparently healthy cattle (n =1,103),
goats (n =248) and, immobilized buffaloes (n =38), zebra (n =2)
and lions (n =2). Sera was eluted and tested for leptospira spp
using Microscopic Agglutination Test (MAT). Laboratory testing
was performed for antibodies against live cultures of six serovars
belonging to the species Leptospira interrogans. Theseserovars
includes: sokoine, lora, kenya, hebdomadis, grippotyphosaandhardjo.
MAT titre ≥ 1:160 was considered positive.
Results: Preliminary results show the overall seroprevalence of
26.35% and 28.57% in domestic animals and wildlife, respectively.
Whereas speciﬁc prevalencewas 30.37% cattle, 8.47% goats, 28.95%
buffaloes and 50% lions. Six serovars of Leptospira Interrogans were
detected in cattle as follow: hardjo (17.6%), hebdomadis (7.7%), grip-
potyphosa (4.8%), sokoine (4.7%) and lora (0.82%). While in goat the
prevalence was sokoine (3.2%), hardjo (2.8%), grippotyphosa (1.6%),
hebdomadis (0.8%) and lora (0.4%). In buffaloes the prevalencewere
hardjo (7.89%), hebdomadis (7.89%) sokoine (5.26%), lora (5.26%)
and grippotyphosa (5.26%). In lion serovars: hardjo (50%) and grip-
potyphosa (50%) were detected. Mixed infection was observed as
follows: - 5.71% in cattle and 0.81% in goats.
Conclusion: These results demonstratedhighprevalence of lep-
tospira infection both in livestock and wildlife species in Katavi.
This is probably the ﬁrst report of leptospirosis infection in Katavi
ecosystem and only report of the disease in goats andwildlife hosts
in the country. These ﬁndings suggest that leptospira is a serious
public and animal health problem in the Katavi and therefore high-
light the urgent need to increase awareness among potential stake
holders so as to be able to reduce the number of current infections
and also prevent further spread.
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Community-directed treatment of NTDs:
Research to community action
U. Amazigo
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Community-directed treatment (CDT), a product of research has
improved access of poor populations in remote villages to health
interventions. The introduction of CDT, a health intervention in
which community members themselves lead the process of drug
delivery and treatment brought dramatic improvements in the
coverage of endemic communities and affected persons receiv-
ing donated medicines annually. In 1997, the number of eligible
persons in Africa receiving ivermectin from health services was
less than 1.5 million. By 2011, a network of 556,000 community-
directed distributors (CDDs) - selected from among their trusted
peers and trained by health workers and non-governmental devel-
opment organizations, administered ivermectin to 80 million
people in 16African countries, preventingmore than 1million peo-
ple fromgoingblind. Recent resultswhich showthatonchocerciasis
might have been eliminated in certain foci in Africa, giving opti-
mism to move from control to elimination of disease, demonstrate
that the poor have successfully applied a research-based strategy
on a regional scale, in partnership with development partners. This
low-cost, community ownership approach is now widely used to
administer anti-lymphatic ﬁlarial and other medicines for the con-
trol and elimination of neglected tropical diseases (NTDs). Lessons
from implementation research, community action, future promise
and challenges of CDT are discussed.
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New diagnostics for childhood pneumonia
D. Murdoch
University of Otago, Christchurch, New Zealand
Identifying the microbial aetiology of pneumonia is challeng-
ing in children. The routine laboratory evaluation of patients with
pneumonia continues to rely on methods that have been used
for decades. While there have been reﬁnements in these tradi-
tional laboratory tools, they have led to onlymodest improvements
in overall diagnostic capability. Recent advances in pneumonia
diagnostics have most notably occurred in nucleic acid detec-
tion. Nucleic acid detection methods, such as PCR, have greatly
improved the ability of diagnostic laboratories to identify pneu-
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monia pathogens, especially respiratory viruses. Indeed, because
of these methods, it is now much easier to conﬁdently diagnose a
viral thanbacterial cause of a respiratory tract infection.Diagnosing
a bacterial aetiology of pneumonia remains problematic, although
may be improved with use of quantitative approaches that are the
focus of ongoing research. There is a pressing need for completely
newapproaches topneumoniadiagnostics, particularlyapproaches
that candistinguish colonising from infectingmicroorganisms, that
can distinguish recent from past infection, that account for host
responsiveness, and can utilise samples that are easy to obtain.
http://dx.doi.org/10.1016/j.ijid.2014.03.461
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Clinical spectrum and complications of
childhood pneumonia in the era of bacterial
conjugate vaccines
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Pneumonia remains a leading cause of under-5 childhood mor-
tality, particularly in low andmiddle-income countries. The rollout
of conjugate bacterial vaccines, including Haemophilus inﬂuenzae
type b conjugate vaccine (HibCV) and particularly pneumococ-
cal conjugate vaccine (PCV), into national immunization programs
recently, has been associated with dramatic decline in all-cause
pneumonia hospitalization in many developed countries where
PCV immunizationhas been implemented. Also, PCV immunization
has variably been associated with changes in incidence of hospi-
talization due to inﬂuenza virus and RSV-associated pneumonia
in some settings. There is, however, limited data from low and
middle-income countries on the effectiveness of PCV against pneu-
monia once introduced into immunization programs. A broader
diversity of serotypes associated with pneumococcal disease and
higher prevalence of underlying risk factors for pneumonia such as
greater prevalence of malnutrition, HIV-infection and tuberculosis
may affect the impact of PCV on all-cause pneumonia morbidity
and mortality in children. Furthermore, early experience from few
studies in developed countrieswith 7-valent PCV, suggested a tem-
poral association between PCV-7 introduction and an increase in
complicated pneumonia including that due to empyema due to
few serotypes not included in PCV7, but which are now included in
the 10 and 13-valent PCVs formulations currently used. The global
public health value of PCVwill bemeasured by its success in reduc-
ing all-cause childhood pneumonia morbidity and mortality in low
and middle-income countries. Results on the impact of PCV immu-
nization in early-adopting low and middle incoming countries are
imminent and will contribute in determining the potential of PCV
in improving child health globally.
http://dx.doi.org/10.1016/j.ijid.2014.03.462
Type: Invited Presentation
Final Abstract Number: 09.003
Session: Childhood and Adult Pneumonia in the Era of Conjugate Vac-
cines
Date: Thursday, April 3, 2014
Time: 15:45-17:45
Room: Auditorium 2
Future Streptococcus pneumoniae vaccines
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The goal of PATH’s pneumococcal vaccine project is to accel-
erate the development of promising new pneumococcal vaccines
that are safe and effective in young children, and to ensure their
affordability, availability, and use in developing countries. As part
of this project, we are developing a portfolio of vaccine candi-
dates with a particular emphasis on common protein vaccines.
Vaccines containing proteins that are common to all pneumococ-
cal serotypes could provide broad and affordable protection to
children worldwide. Our lead protein vaccine strategy involves
the development of an inactivated, whole cell vaccine (SPWCV)
designed to offer broad serotype-independent coverage coupled
with low manufacturing costs. Preclinical studies have demon-
strated protection against both nasopharyngeal carriage (T-cell
mediated) and invasive disease (antibody mediated). We recently
completed a randomized, double blind, placebo-controlled Phase 1
study designed to assess the safety, tolerability and immunogenic-
ity of SPWCV formulated with aluminum hydroxide (PATH-wSP)
in healthy adults. PATH-wSP was found to be safe and well toler-
ated. PATH-wSPelicited signiﬁcant immunoglobulinG responses to
pneumococcal antigens, including pneumococcal surface protein A
(PspA) and pneumolysin, as measured by a variety of immunoas-
says, including enzyme-linked immunosorbent assay (ELISA) and
Meso Scale Discovery (MSD) multiplex assay. Functional antibody
responses were detectable by either passive transfer of protection
tomice or elicitation of pneumolysin toxin neutralizing antibodies.
Signiﬁcant increases in T-cell cytokine responses, including IL-17,
were seen among subjects receiving the 600g dose level of PATH-
wSP.
We are also exploring strategies to incorporate commonprotein
antigens into a limited-valency pneumococcal conjugate vaccine
(PCV). This hybrid approach is designed to take advantage of the
regulatory path established for licensure of new PCVs and to offer
the further beneﬁt of broader coverage by adding a pneumococ-
cal protein antigen. Overall, pneumococcal protein vaccines offer
considerable promise, either alone or in combination with PCVs;
yet the clinical and regulatory challenges for eventual licensure are
considerable.
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